China Medical GatewayLoading your healthcare gateway…

Gastric Cancer in China

Overview

Gastric (stomach) cancer is strongly linked to Helicobacter pylori infection and chronic gastritis. East Asian centers — including China’s — hold the world’s deepest experience in screening gastroscopy, endoscopic resection of early cancer and D2 radical surgery.

For early lesions, endoscopic submucosal dissection can cure the cancer while preserving the stomach; for advanced disease, perioperative chemotherapy and precision drug therapy follow international benchmarks.

Symptoms & Signs

Persistent indigestion or upper abdominal discomfort unrelieved by usual measures

Early fullness when eating and nausea

Black stools or anemia from chronic blood loss

Unexplained weight loss and loss of appetite

Vomiting, sometimes of blood, in advanced tumors

Early gastric cancer is usually silent and found on screening gastroscopy

Diagnosis

Gastroscopy with targeted biopsy — the definitive test

Endoscopic ultrasound assessing tumor depth for endoscopic resection planning

CT of chest, abdomen and pelvis for staging; PET-CT in selected cases

H. pylori testing with eradication therapy when positive

HER2, MSI and CLDN18.2 molecular profiling guiding advanced-disease therapy

Laparoscopy excluding peritoneal spread before surgery in locally advanced disease

Treatment Options

Endoscopic submucosal dissection (ESD) for early cancers meeting curative criteria — stomach-preserving

Laparoscopic or robotic gastrectomy with D2 lymphadenectomy for resectable disease

Perioperative (neoadjuvant plus adjuvant) chemotherapy for locally advanced cancer

HER2-targeted therapy, immunotherapy and second-line chemotherapy for advanced disease

Intraperitoneal chemotherapy for selected peritoneal involvement

Nutritional support and post-gastrectomy care programs

Advanced Technologies & Novel Drug

ESD and EFTR organ-preserving endoscopic resection platforms

ICG fluorescence-guided lymph node dissection during gastrectomy

Robotic and 3D-laparoscopic surgical systems

Fast-track recovery (ERAS) protocols

Novel CLDN18.2-targeted antibody therapy approved and available at Chinese cancer centers

Hospital & Specialist

Return to Home